Metformin exerts antitumor effects mainly through AMP-activated protein kinase [AMPK]
activation and phosphatidylinositol 3-kinase [PI3K]-Akt-mammalian target of rapamycin …

Objective There is increasing pre-clinical and clinical evidence that metformin, a commonly
used diabetes medication, has a protective effect in cancer. The aim of this review is to …

Objective The aim of this study was to review the underlying biologic mechanisms of
metformin's antitumorigenic effects. We assessed the epidemiologic and preclinical data that …

Metformin is a first-line drug used for the treatment of type 2 diabetes. Recently, metformin
has been reported to reduce the carcinogenic risk and inhibit tumor cell growth in glioma …

In recent years, several studies have presented evidence suggesting a potential role for
metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer …

In recent decades, great interest in the off-label use of metformin has arisen as a result of its
broad effects on different signaling pathways, with only a few side effects, and low cost …

Laboratory research and pharmacoepidemiology are providing converging evidence that
the widely used antidiabetic drug metformin has antineoplastic activity, but there are …

Background To investigate whether metformin monotherapy or adjunctive therapy improves
the prognosis in patients with any type of cancer compared to non-metformin users (age≥ …

Background Recently, metformin, first-line drug for type 2 diabetes, has been reported to
treat some gynecological tumors. However, these epidemiological studies have never been …

Simple Summary The potential effects of metformin in terms of cancer prevention and
therapy have been widely studied, and a number of studies have indicated its potential role …